Suppression of ATM kinase signaling accelerates cellular senescence Authors: Kei-ichi Ishikawa, Takahiro Shiga, Takumi Hirose, Naoko Kuzumaki, Sakura Miyoshi, Akihiro Yamaguchi, Hidetaka Tamune, Avijite Kumer Sarkar, Kento Nakai, Kazuyoshi Baba, Shigeo Okabe, Nobutaka Hattori, Hideyuki Okano, Wado Akamatsu Published: 2026 ABSTRACT SummaryCells derived from rejuvenated human induced pluripotent stem cells (hiPSCs) require extended culture periods to achieve functional maturation, and it remains difficult to recapitulate cellular senescence in these cells in vitro. This limitation hinders the accurate and efficient modeling of age-related neurodegenerative diseases. Here, we aimed to establish a simple approach to promote neuronal maturation and improve the efficiency of hiPSC-based disease modeling. Using a small-molecule inhibitor library, we identified an ATM kinase inhibitor, KU60019, that promotes both maturation-associated features and senescence-associated phenotypes in hiPSC-derived neurons and fibroblasts. KU60019 treatment promoted the manifestation of disease-relevant phenotypes in hiPSC models of age-related neurodegenerative diseases. Furthermore, senolytic analyses suggested that KU60019-induced senescent cells depend on pro-survival pathways, including HSP90-associated signaling. These findings suggest that KU60019 provides a simple and useful tool for accelerating phenotypic recapitulation in hiPSC models of age-related neurodegenerative diseases. Introduction Human induced pluripotent stem cell (hiPSC)-based disease models are particularly valuable in neurological disease research because they recapitulate human nervous system pathology in vitro. iPSCs, reprogrammed from somatic cells into pluripotent stem cells, are similar to embryonic stem cells. However, most neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), typically develop after the age of 50. Although pathological changes begin at the cellular level in the prodromal stage, long-term culture is required to reproduce pathological phenotypes in hiPSC models (Okano and Morimoto, 2022). Moreover, although maturation of hiPSC-derived neurons progresses during the culture period, it takes more than 7 weeks to achieve spontaneous activity characteristic of mature neurons in adherent cultures, and this activity declines after 30 weeks (Odawara et al., 2016). Cortical organoids cultured for over 40 weeks recapitulate aspects of in vivo neuron maturation but resemble premature infant brains (24–38 weeks postmenstrual age) (Trujillo et al., 2019). Thus, reproducing aging in hiPSC-derived neurons through long-term culture remains challenging, and novel strategies to induce senescence are required to more accurately model age-related neurodegenerative diseases (de Luzy et al., 2024; Jothi and Kulka, 2024). Several strategies have been proposed to induce artificial senescence by regulating aging-related genes, including the introduction of progerin (Miller et al., 2013), knockdown of SATB1 (a nuclear matrix protein) (Riessland et al., 2019; Russo et al., 2024), and knockdown of RANBP17 (a nuclear transport receptor) (Mertens et al., 2015). Although these approaches can induce senescence-like phenotypes in hiPSC-derived neurons, they are technically complex and difficult to standardize in terms of throughput, efficiency, and uniformity. Dopaminergic neurons derived from telomerase inhibitor-treated iPSCs exhibited aging-associated phenotypes. However, although long-term culture reduced the number of tyrosine hydroxylase (TH)-positive neurons in PD-derived cells, a similar effect was observed in control neurons (Vera et al., 2016). Drug screening using neonatal fibroblasts identified an inhibitor cocktail comprising a ULK1 inhibitor (SBI-0206965), which suppresses autophagy, and a DNA glycosylase inhibitor (O151), which impairs DNA repair. This combination has been reported to promote senescence-like and disease-associated phenotypes in hiPSC-derived neurons from patients with amyotrophic lateral sclerosis (Fathi et al., 2022). Recently, a genome-wide CRISPR screen using iPSC-derived neurons carrying familial AD mutation, with cell death as a readout, identified neddylation-related genes. Treatment with a neddylation inhibitor, MLN4924, has been shown to promote aging-associated and disease-relevant phenotypes of neurodegenerative diseases in iPSC-derived neurons (Saurat et al., 2024). In this study, we aimed to identify compounds that promote the maturation of hiPSC-derived neurons and improve the efficiency of modeling late-onset neurodegenerative diseases. We identified an ATM (ataxia telangiectasia mutated) kinase inhibitor, KU60019, that promotes neuronal maturation. ATM is a central regulator of the DNA damage response, and its inhibition accelerates the manifestation of disease-relevant phenotypes by inducing an aging-like state in hiPSC-derived neurons. Results Screening of compounds that promote the maturation of hiPSC-derived neurons To identify compounds that accelerate the maturation of hiPSC-derived neurons, we screened an inhibitor library containing 111 compounds (Sigma-Aldrich, BMINH02MARUN). An overview of the screening process is presented in Figure 1A. Neurons were generated from healthy human iPSCs (201B7) using neurosphere-based differentiation. Neural progenitors derived from neurospheres were transduced with a lentiviral vector encoding a GFP reporter driven by the synapsin promoter (Synapsin-GFP) on day 0. The synapsin promoter was used as a readout of neuronal maturation, as synapsin expression increases during synapse formation and functional maturation. Compound treatment was initiated at this stage, when cells remained immature neuronal progenitors, to capture the effects of compounds on the transition toward more mature neuronal phenotypes. After 24 h, the medium was replaced with fresh medium containing 10 μM of each compound, and neuronal maturation was evaluated on day 17 based on the fluorescence intensity of Synapsin-GFP (Figure 1A; Table S1). The highest fluorescence intensity relative to astrocyte-conditioned medium (ACM), used as a positive control, was observed in neurons treated with KU60019, an ATM kinase inhibitor (Figure 1B).Figure 1Screening identifies compounds that promote the maturation of hiPSC-derived neurons(A) Schematic overview of the compound screening strategy using Synapsin-GFP as a reporter of neuronal maturation in hiPSC-derived neurons.(B) Screening results based on Synapsin-GFP fluorescence intensity.(C) Representative images of immunostaining for the neuronal marker β3-tubulin, the dopaminergic marker TH, and the midbrain progenitor marker FOXA2 in untreated and KU60019-treated dopaminergic neurons after 14 days of differentiation.(D–F) Quantification of β3-tubulin-, TH-, and FOXA2-positive cells. Scale bars, 100 μm. n = 5 independent experiments.(G) Representative images of untreated and KU60019-treated dopaminergic neurons labeled with AAV1-tdTomato for neurite length analysis. Scale bars: 50 μm (days 3 and 5) and 200 μm (day 7).(H) Dot plot showing neurite length. Data were obtained from n = 3 independent experiments (11–46 cells analyzed per experiment). Black dots indicate means, and error bars represent 95% confidence intervals. Mean differences (Δmean) and effect sizes (Hedges’ g) are indicated.(I) Representative membrane potential traces during hyperpolarizing and depolarizing current injections (−60, 0, and 60 pA for 300 ms) recorded on day 35. Repetitive action potentials were evoked by injection of a 60-pA current. Unless otherwise indicated, data are shown as mean ± SEM. p values were calculated using Welch’s t test. N.S., not significant. See also Figure S1 and Table S1. Screening identifies compounds that promote the maturation of hiPSC-derived neurons (A) Schematic overview of the compound screening strategy using Synapsin-GFP as a reporter of neuronal maturation in hiPSC-derived neurons. (B) Screening results based on Synapsin-GFP fluorescence intensity. (C) Representative images of immunostaining for the neuronal marker β3-tubulin, the dopaminergic marker TH, and the midbrain progenitor marker FOXA2 in untreated and KU60019-treated dopaminergic neurons after 14 days of differentiation. (D–F) Quantification of β3-tubulin-, TH-, and FOXA2-positive cells. Scale bars, 100 μm. n = 5 independent experiments. (G) Representative images of untreated and KU60019-treated dopaminergic neurons labeled with AAV1-tdTomato for neurite length analysis. Scale bars: 50 μm (days 3 and 5) and 200 μm (day 7). (H) Dot plot showing neurite length. Data were obtained from n = 3 independent experiments (11–46 cells analyzed per experiment). Black dots indicate means, and error bars represent 95% confidence intervals. Mean differences (Δmean) and effect sizes (Hedges’ g) are indicated. (I) Representative membrane potential traces during hyperpolarizing and depolarizing current injections (−60, 0, and 60 pA for 300 ms) recorded on day 35. Repetitive action potentials were evoked by injection of a 60-pA current. Unless otherwise indicated, data are shown as mean ± SEM. p values were calculated using Welch’s t test. N.S., not significant. See also Figure S1 and Table S1. To investigate the effects and safety of KU60019 on hiPSC-derived neurons, hiPSC-derived midbrain dopaminergic neurons were treated with this inhibitor. Because treatment with 10 μM KU60019 was neurotoxic, the treatment concentration was set to 5 μM (Figure S1). KU60019 treatment (5 μM) did not significantly affect the percentages of cells positive for the neuronal marker β3-tubulin, the dopaminergic neuron marker TH, and the midbrain dopaminergic neuron progenitor cell marker FOXA2 (Figures 1C–1F). These results indicate that KU60019 does not alter neuronal identity or lineage specification during differentiation of hiPSCs into dopaminergic neurons. Furthermore, we examined the effect of KU60019 on neuronal maturation by measuring neurite length. Dopaminergic neurons treated with KU60019 exhibited significantly longer neurites than untreated neurons after 5 and 7 days of treatment (Figures 1G and 1H). Functional maturation was subsequently assessed using patch-clamp recordings. Dopaminergic neurons treated with KU60019 exhibited higher frequencies of action potential firing in response to current injection than untreated neurons at day 35 (Figure 1I). Collectively, these results suggest that KU60019 promotes the maturation of hiPSC-derived dopaminergic neurons without affecting their differentiation efficiency. KU60019 induces senescence-associated phenotypes in hiPSC-derived dopaminergic neurons KU60019 is an ATM kinase inhibitor, and the ATM pathway has been implicated in cellular senescence (Dong et al., 2022). Given that KU60019 was identified as a maturation-promoting compound in our screen, we hypothesized that it may influence senescence-related processes in hiPSC-derived dopaminergic neurons. To test this possibility, we performed staining for senescence-associated β-galactosidase (SA-βGal), a marker of senescent cells. KU60019 treatment significantly increased the number of SA-βGal-positive dopaminergic neurons (Figures 2A and 2B). Because SA-βGal staining can also be induced by cellular stress, additional markers were analyzed to further characterize SA-βGal-positive cells (Alessio et al., 2021; Yang and Hu, 2005). Most SA-βGal-positive cells were classified as senescent (pRPS6+, Ki67−) or pre-senescent (pRPS6−) cells. KU60019 treatment predominantly increased the proportion of senescent cells, whereas stressed (pRPS6+, Ki67+) cells were rarely detected (Figures S2A and S2B). This trend was consistently observed across the two hiPSC-derived neuronal lines examined.Figure 2KU60019 induces senescence-associated phenotypes in hiPSC-derived dopaminergic neurons(A) Representative images of SA-βGal staining and MAP2 immunostaining in untreated and KU60019-treated hiPSC-derived dopaminergic neurons after 14 days of differentiation. Scale bars, 100 μm.(B) Percentage of SA-βGal+ cells. n = 5 independent experiments.(C) Representative images of γH2AX and MAP2 immunostaining in untreated and KU60019-treated neurons on day 14. Magnified views are shown on the right. Scale bars: 100 μm (left) and 10 μm (right).(D) Percentage of γH2AX-positive cells. Nuclei containing ≥3 γH2AX foci were defined positive. Data were obtained from n = 3 independent experiments (77–192 cells analyzed per experiment).(E) Representative images of lamin B1 and MAP2 immunostaining in untreated and KU60019-treated neurons on day 14. Magnified views are shown on the right. Scale bars: 100 μm (left) and 10 μm (right).(F) Percentage of cells with abnormal nuclear morphology at days 3, 7, and 14. Data are shown as mean ±95% CI from n = 6 independent experiments. Statistical significance was assessed using two-way ANOVA (treatment × time), followed by Holm-adjusted post hoc comparisons at each time point.(G and H) Gene expression levels of lamin B1 (G) and lamin B2 (H) in untreated and KU60019-treated neurons measured on day 23. n = 4 independent experiments.(I) Representative images of MAP2 and p62 immunostaining in untreated and KU60019-treated neurons on day 14. Magnified views are shown on the right. Scale bars: 100 μm (left) and 20 μm (right).(J) Immunoblot analysis of LC3 and p62 expression in untreated and KU60019-treated neurons on day 14. n = 3 independent experiments.(K) NAD/NADH ratio in untreated and KU60019-treated neurons on day 14. n = 6 independent experiments.(L and M) Gene expression levels of the NAD biosynthesis enzymes NAMPT (L) and NMNAT (M) in untreated and KU60019-treated neurons on day 14. n = 4 independent experiments. Unless otherwise indicated, data are shown as mean ± SEM. p values were calculated using Welch’s t test, except for (F). See also Figures S2 and S3. KU60019 induces senescence-associated phenotypes in hiPSC-derived dopaminergic neurons (A) Representative images of SA-βGal staining and MAP2 immunostaining in untreated and KU60019-treated hiPSC-derived dopaminergic neurons after 14 days of differentiation. Scale bars, 100 μm. (B) Percentage of SA-βGal+ cells. n = 5 independent experiments. (C) Representative images of γH2AX and MAP2 immunostaining in untreated and KU60019-treated neurons on day 14. Magnified views are shown on the right. Scale bars: 100 μm (left) and 10 μm (right). (D) Percentage of γH2AX-positive cells. Nuclei containing ≥3 γH2AX foci were defined positive. Data were obtained from n = 3 independent experiments (77–192 cells analyzed per experiment). (E) Representative images of lamin B1 and MAP2 immunostaining in untreated and KU60019-treated neurons on day 14. Magnified views are shown on the right. Scale bars: 100 μm (left) and 10 μm (right). (F) Percentage of cells with abnormal nuclear morphology at days 3, 7, and 14. Data are shown as mean ±95% CI from n = 6 independent experiments. Statistical significance was assessed using two-way ANOVA (treatment × time), followed by Holm-adjusted post hoc comparisons at each time point. (G and H) Gene expression levels of lamin B1 (G) and lamin B2 (H) in untreated and KU60019-treated neurons measured on day 23. n = 4 independent experiments. (I) Representative images of MAP2 and p62 immunostaining in untreated and KU60019-treated neurons on day 14. Magnified views are shown on the right. Scale bars: 100 μm (left) and 20 μm (right). (J) Immunoblot analysis of LC3 and p62 expression in untreated and KU60019-treated neurons on day 14. n = 3 independent experiments. (K) NAD/NADH ratio in untreated and KU60019-treated neurons on day 14. n = 6 independent experiments. (L and M) Gene expression levels of the NAD biosynthesis enzymes NAMPT (L) and NMNAT (M) in untreated and KU60019-treated neurons on day 14. n = 4 independent experiments. Unless otherwise indicated, data are shown as mean ± SEM. p values were calculated using Welch’s t test, except for (F). See also Figures S2 and S3. To further assess KU60019-induced senescence in hiPSC-derived dopaminergic neurons, we evaluated multiple senescence-associated phenotypes, including increased DNA damage, abnormal nuclear morphology, altered lamin B1 and B2 expression, proteolytic dysfunction, altered NAD metabolism, and the formation of cytoplasmic chromatin fragments (CCFs). In the immunostaining-based analyses, quantification was performed in MAP2-positive cells. KU60019 treatment significantly increased the number of neurons with three or more γH2AX foci in the nucleus, indicating DNA damage accumulation (Figures 2C and 2D). KU60019 treatment for more than 7 days also increased the number of cells with abnormal nuclear membrane structures, as indicated by reduced lamin B1 fluorescence (Figures 2E and 2F). Moreover, lamin B1 and B2 expression levels showed a decreasing trend (Figures 2G and 2H). Furthermore, KU60019 treatment increased the intracellular accumulation of the autophagy substrate p62 and upregulated the expression of the autophagosome marker LC3-II in dopaminergic neurons, suggesting autophagic dysfunction (Figures 2I and 2J). Compared with untreated cells, KU60019 treatment decreased the NAD/NADH ratio in dopaminergic neurons; however, the expression levels of NAMPT and NMNAT, key enzymes in NAD biosynthesis, were unaffected (Figures 2K–2M). Although KU60019 treatment did not significantly increase CCF formation when assessed using multiple markers (Ivanov et al., 2013), most effect sizes were moderate to large, suggesting a potential increase across the two hiPSC-derived neuronal lines (Figures S2C–S2E). Overall, these results are consistent with previous findings in physiologically senescent cells (López-Otín et al., 2023) and suggest that KU60019 induces senescence-like phenotypes in hiPSC-derived neurons, a property that was not the primary focus of the maturation-based screen. To confirm that the effects of KU60019 were independent of the applied differentiation method, the floor plate method was used to obtain dopaminergic neurons (Gantner et al., 2020). Consistent with the results obtained using neurosphere-based differentiation, KU60019 treatment induced cellular senescence-associated phenotypes in dopaminergic neurons generated by the floor plate method without affecting differentiation (Figure S3). KU60019 induces aging-associated phenotypes in young fibroblasts resembling physiological aging To evaluate the similarity between KU60019-induced and physiologically aged senescence, we treated young fibroblasts from a healthy 17-year-old donor with KU60019 and compared their phenotypes with those of aged fibroblasts from a healthy 66-year-old donor. The percentage of SA-βGal-positive cells was low in young fibroblasts (13 ± 2.77%), but high in aged fibroblasts (40 ± 2.16%). However, treatment of young fibroblasts with KU60019 increased the percentage of SA-βGal-positive cells to 81 ± 3.54% (Figures 3A and 3B). Further analysis confirmed that this increase was mainly due to an expansion of pre-senescent and senescent cell populations, whereas stressed cells increased only minimally (Figures S4A and S4B). γH2AX and 53BP1 foci are markers of double-strand DNA breaks (DSBs), which decrease with aging in quiescent cells, including mature neurons, but increase with aging in proliferating cells, such as fibroblasts (Zorin et al., 2019). KU60019 treatment reduced γH2AX and 53BP1 foci in young fibroblasts, suggesting impaired DNA damage responses (Figures 3C–3E). Consistent with results in aged fibroblasts, KU60019 treatment reduced lamin B1 localization at the nuclear rim in young fibroblasts (Figures 3F and 3G). Changes in autophagy were assessed based on p62 and LC3 levels. Aged fibroblasts exhibited higher levels of p62 and LC3-II than young fibroblasts; similarly, KU60019 treatment increased p62 and LC3-II levels in young fibroblasts (Figures 3H and 3I). Analysis of CCF formation using multiple markers showed that KU60019 treatment significantly increased CCF formation for most markers examined (Figures S4C–S4F). To further examine SASP following KU60019 treatment, we performed a cytokine array analysis of conditioned media. A coordinated trend toward increased secretion of multiple cytokines, including IL-1α, IL-1β, IL-8, TGF-β, and TNF-α, was observed (Figure S5). Additionally, KU60019 treatment induced similar changes in senescence-associated markers, such as lamin B1 and p62, in SH-SY5Y cells (Figure S6). These results indicate that KU60019 induces cellular senescence-associated phenotypes across multiple cell types.Figure 3KU60019 induces aging-associated phenotypes in young fibroblasts resembling physiological aging(A) Representative images of SA-βGal staining in untreated young, KU60019-treated young, and aged fibroblasts. Scale bars, 100 μm.(B) Percentage of SA-βGal+ cells. n = 3 independent experiments.(C) Representative images of γH2AX (upper images) and 53BP1 (lower images) immunostaining. Scale bars, 10 μm.(D and E) Percentage of nuclei containing ≥3 γH2AX foci (D) or ≥3 53BP1 foci (E). n = 3 independent experiments.(F) Representative images of lamin B1 immunostaining. Scale bars, 10 μm.(G) Percentage of cells with abnormal nuclear morphology. n = 6 independent experiments.(H) Representative images of LC3 and p62 immunostaining.(I) Immunoblot analysis of LC3 and p62 expression. n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using Welch’s ANOVA followed by Holm-adjusted Games-Howell post hoc comparisons. See also Figures S4–S7. KU60019 induces aging-associated phenotypes in young fibroblasts resembling physiological aging (A) Representative images of SA-βGal staining in untreated young, KU60019-treated young, and aged fibroblasts. Scale bars, 100 μm. (B) Percentage of SA-βGal+ cells. n = 3 independent experiments. (C) Representative images of γH2AX (upper images) and 53BP1 (lower images) immunostaining. Scale bars, 10 μm. (D and E) Percentage of nuclei containing ≥3 γH2AX foci (D) or ≥3 53BP1 foci (E). n = 3 independent experiments. (F) Representative images of lamin B1 immunostaining. Scale bars, 10 μm. (G) Percentage of cells with abnormal nuclear morphology. n = 6 independent experiments. (H) Representative images of LC3 and p62 immunostaining. (I) Immunoblot analysis of LC3 and p62 expression. n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using Welch’s ANOVA followed by Holm-adjusted Games-Howell post hoc comparisons. See also Figures S4–S7. ATM, ATR (ataxia-telangiectasia and Rad3-related), and the MRN complex (MRE11, RAD50, and NBS1) are central components of the DNA damage response (DDR) to DSBs and coordinate DNA repair and cell-cycle progression (Figure S7A). To determine whether inhibition of other DDR-related components similarly promotes senescence-associated phenotypes, we examined the effects of additional ATM inhibitors (KU55933 and AZD0156), an ATR inhibitor (VE821), and an MRN complex inhibitor (MIRIN). KU60019, AZD0156, and MIRIN significantly increased the proportion of SA-βGal-positive cells in young fibroblasts, with KU60019 showing the strongest effect (Figures S7B and S7C). KU60019 alters senescence-associated gene expression To evaluate global gene expression changes associated with KU60019-induced senescence, we performed RNA-sequencing of hiPSC-derived dopaminergic neurons treated with or without KU60019 (Table S2). Principal component analysis (PCA) showed that KU60019 treatment significantly altered the gene expression profiles of these neurons compared with untreated controls. The third principal component (PC3) primarily reflected the effect of KU60019 treatment (Figure 4A). Notably, KU60019 treatment resulted in the upregulation of 92 genes and downregulation of 489 genes in dopaminergic neurons (Figure 4B). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that genes downregulated by KU60019 treatment were enriched in pathways related to the cell cycle, p53 signaling, cellular senescence, DNA replication, homologous recombination (HR), and the Fanconi anemia pathway (Figure 4C). These transcriptional changes are consistent with stable cell-cycle arrest and suppression of proliferation-associated DNA replication and repair programs, which are characteristic features of senescent cells. Although the “cellular senescence” pathway was also identified among the downregulated pathways, this likely reflects suppression of proliferation- and DNA repair-related components included in the pathway rather than an absence of senescence. Together with the observed senescence-associated phenotypes, these results indicate that KU60019 induces a senescence-like transcriptional program in hiPSC-derived dopaminergic neurons.Figure 4KU60019 induces senescence-associated and DNA damage response-related transcriptional changes(A) Three-dimensional PCA plots of normalized transcriptome data from three hiPSC-derived dopaminergic neuronal lines (blue) and KU60019-treated neurons (orange). Dashed circles indicate samples derived from the same hiPSC line.(B) Heatmap of significantly altered genes (adjusted p < 0.05) in neurons following KU60019 treatment.(C) KEGG pathway enrichment analysis of genes significantly downregulated following KU60019 treatment in neurons. Bars represent fold enrichment.(D and E) Volcano plots of untreated versus KU60019-treated young fibroblasts (D) and young versus aged fibroblasts (E). Differentially expressed genes (adjusted p < 0.05) are highlighted in blue (downregulated) and red (upregulated).(F) Three-dimensional PCA plots of normalized transcriptome data from untreated young (blue), KU60019-treated young (orange), and aged (green) fibroblasts.(G) Hierarchical clustering dendrograms of transcriptome data from young, KU60019-treated young, and aged fibroblasts.(H) Heatmap of differentially expressed genes in young, KU60019-treated young, and aged fibroblasts.(I and J) KEGG pathway enrichment analysis of genes significantly downregulated (I) and upregulated (J) in young fibroblasts following KU60019 treatment. Bars represent fold enrichment. Adjusted p values were calculated using likelihood ratio tests (LRTs) implemented in edgeR. See also Figure S8 and Tables S2 and S3. KU60019 induces senescence-associated and DNA damage response-related transcriptional changes (A) Three-dimensional PCA plots of normalized transcriptome data from three hiPSC-derived dopaminergic neuronal lines (blue) and KU60019-treated neurons (orange). Dashed circles indicate samples derived from the same hiPSC line. (B) Heatmap of significantly altered genes (adjusted p < 0.05) in neurons following KU60019 treatment. (C) KEGG pathway enrichment analysis of genes significantly downregulated following KU60019 treatment in neurons. Bars represent fold enrichment. (D and E) Volcano plots of untreated versus KU60019-treated young fibroblasts (D) and young versus aged fibroblasts (E). Differentially expressed genes (adjusted p < 0.05) are highlighted in blue (downregulated) and red (upregulated). (F) Three-dimensional PCA plots of normalized transcriptome data from untreated young (blue), KU60019-treated young (orange), and aged (green) fibroblasts. (G) Hierarchical clustering dendrograms of transcriptome data from young, KU60019-treated young, and aged fibroblasts. (H) Heatmap of differentially expressed genes in young, KU60019-treated young, and aged fibroblasts. (I and J) KEGG pathway enrichment analysis of genes significantly downregulated (I) and upregulated (J) in young fibroblasts following KU60019 treatment. Bars represent fold enrichment. Adjusted p values were calculated using likelihood ratio tests (LRTs) implemented in edgeR. See also Figure S8 and Tables S2 and S3. Furthermore, we performed RNA-sequencing to elucidate the mechanism by which KU60019 promotes senescence-associated changes in fibroblasts (Table S3). KU60019 treatment upregulated 629 genes and downregulated 630 genes in young fibroblasts (Figure 4D). Compared with young fibroblasts, 713 and 715 genes were upregulated and downregulated, respectively, in aged fibroblasts (Figure 4E). PCA showed that KU60019 significantly altered the gene expression profile of young fibroblasts compared with untreated young fibroblasts (Figure 4F). PC1 primarily reflected donor differences between young and aged cells. In contrast, PC2 and PC3 showed that the overall gene expression of KU60019-treated young fibroblasts shifted toward that of aged fibroblasts, separated from untreated young cells. Clustering analyses by dendrograms and heatmaps revealed that young fibroblasts treated with KU60019 had a gene expression pattern similar to physiologically aged fibroblasts (Figures 4G and 4H). These results indicate that KU60019 induces senescence-associated transcriptional changes in young fibroblasts, similar to that observed in physiologically aged cells. Consistent with results in hiPSC-derived neurons, KEGG analysis showed that genes downregulated in KU60019-treated young fibroblasts were enriched in pathways related to the cell cycle, DNA replication, the Fanconi anemia pathway, protein digestion and absorption, HR, base excision repair, and mismatch repair (Figure 4I). These transcriptional changes are consistent with stable cell-cycle arrest and suppression of proliferation-associated DNA replication and DNA repair programs, which are characteristic features of senescent cells. Additionally, upregulated genes were enriched in the lysosomal pathway (Figure 4J), consistent with previous findings that lysosomal protein expression, such as v-ATPase, is increased following ATM inhibition (Kang et al., 2017). Across hiPSC-derived dopaminergic neurons and young fibroblasts treated with KU60019, 190 genes were commonly altered (Figures S8A and S8B). Most of the genes were downregulated by KU60019 treatment (Figure S8A), and the top enriched KEGG pathways were related to the cell cycle, the Fanconi anemia pathway, cellular senescence, p53 signaling, HR, and DNA replication (Figures S8C and S8D). These shared transcriptional changes likely reflect coordinated suppression of proliferation- and replication-associated components within these pathways rather than the absence of senescence. Together, these results indicate that KU60019 induces conserved senescence-associated transcriptional programs across multiple cell types. Analysis of survival pathways in KU60019-induced senescence reveals HSP90 dependence To further investigate the mechanisms underlying KU60019-induced senescence, we examined the effects of compounds reported to exhibit senolytic activity, which selectively induce the death of senescent cells, in combination with KU60019. We assessed the viability of KU60019-treated young fibroblasts co-treated with seven such compounds, including rapamycin (Laberge et al., 2015), metformin (Moiseeva et al., 2013), ABT-737 (Yosef et al., 2016), 17DMAG (Fuhrmann-Stroissnigg et al., 2017), azithromycin (Ozsvari et al., 2018), fisetin (Yousefzadeh et al., 2018), and a dasatinib-quercetin combination (Zhu et al., 2015). Among these, ABT-737, a BCL-2 family inhibitor, and 17DMAG, an HSP90 inhibitor, reduced the viability of KU60019-treated fibroblasts, with 17DMAG showing the strongest effect (Figure 5A). The senolytic activity of both compounds was further supported by their ability to reduce the number of KU60019-induced SA-βGal-positive fibroblasts (Figure 5B). These results indicate that both compounds exert senolytic effects on KU60019-induced senescent cells.Figure 5HSP90 and BCL-2 inhibition induce cell death in KU60019-treated cells and suppress senescence-associated phenotypes(A) Cell viability of young fibroblasts treated with the indicated compounds for 24 h in the absence or presence of KU60019. Blue bars represent untreated young fibroblasts, and orange bars represent KU60019-treated young fibroblasts co-treated with the indicated compounds. n = 6 independent experiments.(B) Percentage of SA-βGal+ cells under the indicated conditions (untreated, KU60019, KU60019 + 17DMAG, and KU60019 + ABT-737) in young fibroblasts. n = 6 independent experiments.(C) Representative images of γH2AX (upper images) and lamin B1 (lower images) immunostaining in young fibroblasts under the indicated conditions. Scale bars, 10 μm.(D) Immunoblot analysis of LC3 and p62 protein levels in young fibroblasts under the indicated conditions. n = 3 independent experiments.(E) Representative images of SA-βGal and MAP2 staining in untreated, KU60019-treated, and KU60019 + 17DMAG-treated hiPSC-derived neurons after 14 days of differentiation. Scale bars, 100 μm.(F) Percentage of SA-βGal+ neurons shown in (E). n = 5–6 independent experiments.(G) Immunoblot analysis of cleaved caspase-3 protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated hiPSC-derived neurons. n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using Welch’s ANOVA followed by Holm-adjusted Games-Howell post hoc comparisons. See also Figure S9. HSP90 and BCL-2 inhibition induce cell death in KU60019-treated cells and suppress senescence-associated phenotypes (A) Cell viability of young fibroblasts treated with the indicated compounds for 24 h in the absence or presence of KU60019. Blue bars represent untreated young fibroblasts, and orange bars represent KU60019-treated young fibroblasts co-treated with the indicated compounds. n = 6 independent experiments. (B) Percentage of SA-βGal+ cells under the indicated conditions (untreated, KU60019, KU60019 + 17DMAG, and KU60019 + ABT-737) in young fibroblasts. n = 6 independent experiments. (C) Representative images of γH2AX (upper images) and lamin B1 (lower images) immunostaining in young fibroblasts under the indicated conditions. Scale bars, 10 μm. (D) Immunoblot analysis of LC3 and p62 protein levels in young fibroblasts under the indicated conditions. n = 3 independent experiments. (E) Representative images of SA-βGal and MAP2 staining in untreated, KU60019-treated, and KU60019 + 17DMAG-treated hiPSC-derived neurons after 14 days of differentiation. Scale bars, 100 μm. (F) Percentage of SA-βGal+ neurons shown in (E). n = 5–6 independent experiments. (G) Immunoblot analysis of cleaved caspase-3 protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated hiPSC-derived neurons. n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using Welch’s ANOVA followed by Holm-adjusted Games-Howell post hoc comparisons. See also Figure S9. We next focused on the effects of 17DMAG on KU60019-induced senescent cells. 17DMAG reversed KU60019-induced senescence-associated phenotypes in fibroblasts, including increased γH2AX foci, abnormal lamin B1 distribution, and autophagic dysfunction (Figures 5C and 5D). In hiPSC-derived neurons, 17DMAG abolished the KU60019-induced increase in SA-βGal-positive cells (Figures 5E and 5F). In addition, 17DMAG restored caspase-3/7 activity in KU60019-treated fibroblasts (Figure S9B) and increased cleaved caspase-3 levels in KU60019-treated neurons derived from two independent hiPSC lines (Figures 5G and S9A), indicating the induction of apoptosis. To further investigate HSP90-related pathways, we examined HSP90 isoform expression in neurons derived from two independent hiPSC lines and in fibroblasts. KU60019 treatment did not alter HSP90α expression, whereas HSP90β expression was either unchanged or modestly decreased, depending on the cell type (Figures 6A, S10A, and S11A). Upon co-treatment with 17DMAG, the expression of both HSP90 isoforms tended to increase, consistent with a compensatory response to reduced HSP90 activity (Kim et al., 2017). This trend was observed in neurons derived from two independent hiPSC lines (Figures 6A and S10A) as well as in fibroblasts (Figure S11A), although statistical significance varied between conditions.Figure 6KU60019-induced senescence-associated changes are linked to alterations in NF-κB, Akt, and BCL-2 signaling in neurons(A) Immunoblot analysis of HSP90 protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated hiPSC-derived neurons. n = 3 independent experiments.(B) Immunoblot analysis of NF-κB signaling components and their phosphorylated forms in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments.(C) Immunoblot analysis of Akt and phosphorylated Akt protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments.(D) Immunoblot analysis of Akt-mTOR pathway components and their phosphorylated forms in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments.(E) Immunoblot analysis of BAX and BCL-2 protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using Welch’s ANOVA followed by Holm-adjusted Games-Howell post hoc comparisons. See also Figures S10 and S11. KU60019-induced senescence-associated changes are linked to alterations in NF-κB, Akt, and BCL-2 signaling in neurons (A) Immunoblot analysis of HSP90 protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated hiPSC-derived neurons. n = 3 independent experiments. (B) Immunoblot analysis of NF-κB signaling components and their phosphorylated forms in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments. (C) Immunoblot analysis of Akt and phosphorylated Akt protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments. (D) Immunoblot analysis of Akt-mTOR pathway components and their phosphorylated forms in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments. (E) Immunoblot analysis of BAX and BCL-2 protein levels in untreated, KU60019-treated, and KU60019 + 17DMAG-treated neurons. n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using Welch’s ANOVA followed by Holm-adjusted Games-Howell post hoc comparisons. See also Figures S10 and S11. Given that HSP90 stabilizes numerous client proteins and that its inhibition has been reported to suppress pro-survival signaling pathways, including NF-κB and AKT, we next examined the NF-κB pathway. In hiPSC-derived neurons, KU60019 treatment did not alter the levels of key NF-κB signaling components, including phosphorylated p65 (p-p65), total p65, IKKα, IKKβ, and IκBα (Figure 6B). The expression of RIP1, which functions upstream of the IKK complex as a scaffold protein required for NF-κB activation, was also unchanged (Figure 6B). In contrast, co-treatment with 17DMAG markedly reduced RIP1 and IKKβ levels and decreased p65 phosphorylation, while total p65 levels remained unchanged, indicating suppression of NF-κB signaling (Figure 6B). Similar results were observed in an additional hiPSC-derived neuronal line (Figure S10B) and in fibroblasts (Figure S11B). We next examined the Akt pathway. Total Akt levels and phosphorylation at Thr308 remained unchanged following KU60019 treatment, whereas phosphorylation at Ser473 was reduced (Figure 6C). Because phosphorylation at Ser473 is required for full Akt activation, these results indicate partial attenuation of Akt signaling. Consistent with this, phosphorylation of GSK3β, a downstream substrate negatively regulated by Akt, was also decreased (Figure 6D). To determine whether this reduction in Akt activity affected mTORC1 signaling, we analyzed phosphorylation of the canonical mTORC1 substrates 4EBP1 and p70S6K (Thr389). Phosphorylation of these substrates remained largely unchanged following KU60019 treatment (Figure 6D). In addition, phosphorylation of SGK1 was not altered (Figure 6D). Together, these findings suggest that partial attenuation of Akt signaling did not substantially affect mTORC1 or SGK1 signaling. Upon co-treatment with 17DMAG, total Akt levels were markedly reduced, and phosphorylation at Ser473 was further diminished (Figure 6C). Notably, phosphorylation of p70S6K at Thr389 was increased compared with KU60019 treatment alone, whereas phosphorylation of 4EBP1 remained largely unchanged, and SGK1 phosphorylation was also not significantly altered (Figure 6D). Together, these results suggest that, while NF-κB and Akt signaling pathways are suppressed under combined ATM and HSP90 inhibition, canonical mTORC1 outputs exhibit differential responses. Similar results were observed in an additional hiPSC-derived neuronal line (Figures S10C and S10D). In contrast, in fibroblasts, KU60019 treatment reduced phosphorylation of Akt at Ser473, but no additional effect was observed upon co-treatment with 17DMAG (Figure S11C). These findings suggest that KU60019 selectively impairs Akt signaling without broadly suppressing downstream growth signaling pathways and reveal cell type-specific differences in Akt regulation downstream of HSP90 inhibition. Finally, we examined the BCL-2 pathway implicated by ABT-737. Senescent cells are known to upregulate anti-apoptotic members of the BCL-2 family, thereby suppressing apoptosis and conferring resistance to cell death (Basu, 2022). Consistent with this, KU60019 treatment increased BCL-2 expression and reduced the BAX/BCL-2 ratio in hiPSC-derived neurons (Figure 6E). Similar changes were observed in an additional hiPSC-derived neuronal line (Figure S10E) and in fibroblasts (Figure S11D), suggesting that enhanced anti-apoptotic signaling may contribute to the persistence of KU60019-induced senescent cells. Taken together, these findings indicate that KU60019-induced senescence is maintained by both HSP90-dependent pro-survival signaling and BCL-2-mediated anti-apoptotic pathways. KU60019 treatment accelerates phenotypic recapitulation in hiPSC models of neurodegenerative diseases Given the pro-aging effects of KU60019, we hypothesized that KU60019 may accelerate the phenotypic manifestation of neurodegenerative diseases by inducing senescence-associated phenotypic changes in hiPSC-derived neurons. AD, the most common late-onset neurodegenerative disorder, is caused in part by variants in PSEN1. To assess whether KU60019 promotes amyloid-related phenotypes in PSEN1 variant-carrying neurons, we measured Aβ40 and Aβ42 levels and calculated the Aβ42/Aβ40 ratio at DIV21 and DIV30. At DIV21, no significant genotype-dependent differences were observed without KU60019 treatment. In contrast, under KU60019 treatment, PSEN1-variant neurons showed significantly higher Aβ42 levels than control neurons, whereas Aβ40 levels remained unchanged. The Aβ42/Aβ40 ratio also increased in the same direction, although this difference did not reach statistical significance after multiple-comparison correction (Figures 7A–7C). Previous studies have reported increased p-tau/total tau ratios and enhanced neuronal vulnerability in AD models (Bassil et al., 2021). We next examined tau-related phenotypes in PSEN1 variant-carrying and control hiPSC-derived neurons. At DIV28, the p-Ser202/Thr205 tau/total tau ratio did not differ between PSEN1-variant and control neurons without KU60019 treatment, whereas KU60019 treatment resulted in a significantly higher ratio in PSEN1-variant neurons (Figures 7D and 7E). At DIV42, PSEN1-variant neurons exhibited increased p-tau/total tau ratios both with and without KU60019 treatment, with a more pronounced difference observed following KU60019 treatment (Figures 7D and 7E). In addition, without KU60019 treatment, no significant difference in cell viability was observed between PSEN1-variant and control neurons at day 14, whereas a significant reduction in viability was detected in PSEN1-variant neurons at day 30. In contrast, KU60019 treatment led to a significant decrease in the viability of PSEN1-variant neurons as early as day 14 (Figure 7F).Figure 7KU60019 accelerates the recapitulation of late-onset neurodegenerative disease-associated phenotypes in hiPSC-derived neurons(A–C) Aβ40 levels (A), Aβ42 levels (B), and Aβ42/Aβ40 ratios (C) in control and PSEN1-variant hiPSC-derived neurons at DIV21 and DIV30, measured by ELISA. n = 5–6 independent experiments.(D) Representative images of total tau and phosphorylated tau (p-tau; AT8, Ser202/Thr205) immunostaining in untreated (upper images) and KU60019-treated (lower images) control and PSEN1-variant hiPSC-derived neurons. Scale bars, 50 μm.(E) Quantification of p-tau/total tau fluorescence intensity ratios at DIV28 and DIV42. n = 4 independent experiments.(F) Cell viability of control and PSEN1-variant hiPSC-derived neurons. n = 6 independent experiments.(G–I) Caspase-3/7 activity (G), early apoptosis (Annexin V+/7-AAD− cells) (H), and cell viability (Annexin V−/7-AAD− cells) (I) in three independent control hiPSC-derived neuronal lines and PD hiPSC-derived neurons (PARK2, PARK6, and PARK22). n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using planned Welch’s t tests with Holm correction for multiple comparisons (A–C, E, and F). For (G–I), planned contrasts were used to compare each disease line with the mean of control lines within each set (Welch/linear model-based contrasts with Holm correction). KU60019 accelerates the recapitulation of late-onset neurodegenerative disease-associated phenotypes in hiPSC-derived neurons (A–C) Aβ40 levels (A), Aβ42 levels (B), and Aβ42/Aβ40 ratios (C) in control and PSEN1-variant hiPSC-derived neurons at DIV21 and DIV30, measured by ELISA. n = 5–6 independent experiments. (D) Representative images of total tau and phosphorylated tau (p-tau; AT8, Ser202/Thr205) immunostaining in untreated (upper images) and KU60019-treated (lower images) control and PSEN1-variant hiPSC-derived neurons. Scale bars, 50 μm. (E) Quantification of p-tau/total tau fluorescence intensity ratios at DIV28 and DIV42. n = 4 independent experiments. (F) Cell viability of control and PSEN1-variant hiPSC-derived neurons. n = 6 independent experiments. (G–I) Caspase-3/7 activity (G), early apoptosis (Annexin V+/7-AAD− cells) (H), and cell viability (Annexin V−/7-AAD− cells) (I) in three independent control hiPSC-derived neuronal lines and PD hiPSC-derived neurons (PARK2, PARK6, and PARK22). n = 3 independent experiments. Data are shown as mean ± SEM. p values were calculated using planned Welch’s t tests with Holm correction for multiple comparisons (A–C, E, and F). For (G–I), planned contrasts were used to compare each disease line with the mean of control lines within each set (Welch/linear model-based contrasts with Holm correction). We next examined the effects of KU60019 in hiPSC-derived neurons from patients with PD, another major neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the ventral midbrain. Among inherited forms of PD, PARK2, PARK6, and PARK22 typically present after adolescence but earlier than sporadic PD, with disease severity worsening with age. Previous studies have reported increased caspase-3 activation in dopaminergic neurons derived from patients with these forms of PD (Ikeda et al., 2019; Yamaguchi et al., 2020). In this hiPSC-derived neuronal model, no significant difference in caspase-3/7 activity was observed between control and PD-derived dopaminergic neurons at 14 days after the onset of terminal differentiation (Figure 7G). However, KU60019 treatment significantly increased caspase-3/7 activity in PD-derived neurons compared with controls (Figure 7G). Consistently, in the absence of KU60019 treatment, no significant difference in early apoptotic cells (Annexin V-positive and 7-AAD-negative) was observed between control and PD groups at day 14 (Figure 7H). In contrast, KU60019 treatment significantly increased the proportion of early apoptotic cells in PD-derived dopaminergic neurons (Figure 7H). Moreover, in the absence of KU60019 treatment, the percentage of viable cells (Annexin V-negative and 7-AAD-negative) did not differ between control and PD groups at day 14. In contrast, KU60019 treatment significantly reduced the proportion of viable cells in PD-derived neurons (Figure 7I). Taken together, these results indicate that KU60019 treatment accelerates phenotypic recapitulation in hiPSC-derived models of late-onset neurodegenerative diseases. Discussion In this study, we identified KU60019, an ATM kinase inhibitor, as a compound that promotes the maturation of hiPSC-derived neurons while simultaneously inducing diverse senescence-associated phenotypes. Importantly, KU60019 treatment facilitated the manifestation of disease-relevant phenotypes in hiPSC-derived models of AD and PD within a relatively short culture period. These findings suggest that KU60019 creates a cellular state in which maturation-associated neuronal features and aging-associated phenotypes emerge in parallel, thereby enhancing the utility of hiPSC-based models of late-onset neurodegenerative diseases. Premature aging syndromes are frequently caused by defects in genes responsible for maintaining genomic stability (Schumacher et al., 2021). Ataxia-telangiectasia, caused by mutations in ATM, is a representative disorder characterized by genomic instability and premature aging phenotypes (Barlow et al., 1996; Shiloh and Lederman, 2017). In addition, ATM deficiency has been associated with multiple senescence-related abnormalities, including increased DNA damage, altered nuclear morphology, decreased NAD levels, and neurodegeneration (Barlow et al., 1996; Dong et al., 2022; Fang et al., 2016). Accordingly, patient-derived ATM-mutant brain organoids and mature neurons have been reported to show senescence-associated changes, including activation of senescence-related transcriptional programs, increased SA-βGal staining, and increased p16/p21 expression (Leeson et al., 2024). Consistent with these observations, KU60019-treated cells exhibited similar features, suggesting that ATM inhibition contributes to the induction of an aging-like cellular state. Aging hallmarks are highly interconnected, and DNA damage plays a central role in their regulation (Hou et al., 2019; López-Otín et al., 2023). ATM is a key regulator of the DDR, and pharmacological perturbation of DNA repair pathways has been shown to accelerate aging-associated phenotypes in hiPSC-derived neurons (Fathi et al., 2022; Saurat et al., 2024). However, not all DNA damage-inducing approaches are equally suitable for modeling cellular senescence. Some compounds, such as MLN4924 or O151, require additional conditions or exhibit broad and non-specific effects. In contrast, KU60019 induced coordinated alterations across multiple pathways, including cell-cycle regulation, p53 signaling, and diverse DNA repair pathways. This broad yet structured perturbation likely reflects the central role of ATM in integrating DNA damage signaling, replication stress responses, and cell-cycle control. Therefore, KU60019-mediated senescence is likely driven by the combined impairment of these interconnected mechanisms. Consistent with this notion, KU60019-treated cells exhibited a broad spectrum of senescence-associated phenotypes, including increased SA-βGal activity, autophagic abnormalities, and alterations in protein digestion and absorption pathways, some of which are not directly attributable to canonical ATM signaling. Taken together, these findings suggest that KU60019 can recapitulate multifaceted senescence-like phenotypes. An important conceptual point is that neuronal maturation and cellular senescence are distinct biological processes. Cellular senescence is generally defined as a stress-associated state characterized by cell-cycle arrest and distinct phenotypic changes (Gorgoulis et al., 2019; López-Otín et al., 2023), whereas neuronal maturation reflects developmental progression toward functional competence. Nevertheless, in our experimental system, these processes coexisted. KU60019 was initially identified as a maturation-promoting compound, as evidenced by increased synapsin expression, enhanced axonal elongation, and the emergence of spontaneous neuronal activity within a relatively short time frame. At the same time, it robustly induced senescence-associated phenotypes. These observations suggest that KU60019 does not equate maturation with senescence but rather induces a senescence-associated cellular context in which maturation-associated neuronal features can emerge more rapidly. This interpretation is consistent with previous reports linking senescence-related programs to developmental processes. Cellular senescence has been described as a programmed process during embryonic development, contributing to tissue patterning and morphogenesis (Di Micco et al., 2021). In addition, DNA damage-induced senescence in neural stem cells has been shown to promote differentiation while reducing stemness (Schneider et al., 2013). Thus, ATM signaling may intersect with differentiation programs in the nervous system. In this context, KU60019 treatment during neuronal differentiation may accelerate the transition from progenitor states to functionally mature neurons. Our senolytic screening further suggested that KU60019-induced senescent cells depend on HSP90-associated survival pathways. HSP90 stabilizes multiple client proteins involved in DDR and pro-survival signaling, including ATM, ATR, and AKT (Karayazi Atici et al., 2018; Pennisi et al., 2015). Consistent with previous studies, HSP90 inhibition by 17DMAG induced cell death in KU60019-treated cells. However, inhibition of the PI3K-AKT-mTOR pathway alone by quercetin and fisetin, or by rapamycin, failed to reproduce this effect, suggesting that the cell death-inducing (senolytic) activity of HSP90 inhibition cannot be explained solely by suppression of this pathway. Importantly, ATM inhibition itself appeared to induce a BCL-2-dependent survival state. KU60019 increased BCL-2 expression and reduced the BAX/BCL-2 ratio, and this phenotype was functionally supported by sensitivity to ABT-737. Such anti-apoptotic signaling is a well-recognized feature of senescent cells (Yosef et al., 2016). In this context, HSP90 inhibition likely eliminates these cells by simultaneously disrupting multiple survival pathways, including NF-κB and AKT signaling. Notably, apoptosis was induced despite sustained BCL-2 expression, indicating that mitochondrial protection alone is insufficient when upstream survival signaling is compromised. Taken together, these findings suggest that KU60019 recapitulates key survival features of senescent cells, whereas HSP90 inhibition exploits these vulnerabilities. Several limitations should be considered. First, the relationship between KU60019-induced phenotypes and physiological aging in vitro remains unclear. Our results demonstrate the induction of an aging-like cellular state under specific experimental conditions rather than establishing a direct equivalence with neural aging. Second, although the effects of KU60019 were observed across multiple cell types, their generalizability remains to be determined. Third, the effects of KU60019 appear to be context-dependent. In contrast to our findings, Kang et al. reported that KU60019 alleviated senescence phenotypes in late-passage human neonatal dermal fibroblasts, suggesting that differences in cellular state, treatment duration, and drug concentration may critically influence the outcome of ATM inhibition (Kang et al., 2017). Finally, we did not directly assess cell-cycle dynamics, and the mechanistic relationship between senescence and neuronal maturation remains unresolved. In conclusion, KU60019 induces a senescence-associated cellular state while accelerating maturation-associated neuronal features in hiPSC-derived neurons, thereby enabling more rapid manifestation of disease-relevant phenotypes. By promoting both aging-related and functional neuronal characteristics, KU60019 provides a simple, chemically defined, and practical approach to enhance phenotypic recapitulation in hiPSC models of late-onset neurodegenerative diseases. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by Wado Akamatsu (awado@juntendo.ac.jp). Materials availability This study did not generate new unique reagents. Information on the hiPSC and fibroblast lines used in this study is provided in the key resources table. Data and code availability The data supporting the findings of this study are available within the article and its supplemental information. The RNA-seq data have been deposited in the DDBJ Sequence Read Archive (accession number: PRJDB17588). This study did not generate new code. Acknowledgments This work was supported by the Strategic Research Platform Formation Project for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT; S1411007); the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED; JP17ek0109244 to K.I., N.H., and W.A.); the Acceleration Program of R&D and Implementation for Regenerative Medicine and Cell and Gene Therapy from AMED (JP25bm1423015 to K.I. and W.A.); the Basic Research Program for Drug Discovery Promotion (GAPFREE) from AMED (JP22ak0101112 to K.I., N.H., and W.A., and JP25ak0101236 to N.H. and W.A.); AMED-CREST from AMED (JP24gm1310003 to S.O. and W.A.); JSPS KAKENHI (20K07873 to K.I., 19K16930 to T.S., and 17H05706 to W.A.); and a Grant-in-Aid for Special Research in Subsidies for ordinary expenses of private schools from the Promotion and Mutual Aid Corporation for Private Schools of Japan. We thank Editage (www.editage.com) for English language editing. Author contributions Conceptualization, T.S., K.I., and W.A.; methodology, K.I., T.S., N.K., H.T., A.K.S., K.N., K.B., S.O., N.H., H.O., and W.A.; investigation, K.I., T.S., T.H., N.K., S.M., H.T., A.K.S., and K.N.; writing – original draft, K.I., T.S., and W.A.; writing – review and editing, K.I., T.S., T.H., N.K., S.M., A.Y., H.T., A.K.S., K.N., K.B., S.O., N.H., H.O., and W.A.; visualization, K.I., T.S., T.H., N.K., A.Y., H.T., and A.K.S.; supervision, K.I. and W.A.; project administration, T.S., K.I., and W.A.; funding acquisition, K.I., T.S., S.O., N.H., H.O., and W.A. Declaration of interests The authors declare no competing interests. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodies4EBP1Cell Signaling TechnologyCat#9644; RRID:AB_209784153BP1Cell Signaling TechnologyCat#4937; RRID:AB_10694558AKT (total)Cell Signaling TechnologyCat#9272; RRID:AB_329827BAXCell Signaling TechnologyCat#2772; RRID:AB_10695870BCL-2Santa Cruz BiotechnologyCat#sc-7382; RRID:AB_626736β-actinAbcamCat#ab8227; RRID:AB_2305186β3-tubulinSigma-AldrichCat#T8660; RRID:AB_477590Cleaved caspase-3Cell Signaling TechnologyCat#9661; RRID:AB_2341188FOXA2R&D SystemsCat#AF2400; RRID:AB_2294104GSK3βCell Signaling TechnologyCat#12456; RRID:AB_2636978H3K27me3Active MotifCat#39536; RRID:AB_2793247H3K9acActive MotifCat#39585; RRID:AB_2793268Histone H3Cell Signaling TechnologyCat#4499; RRID:AB_10544537HSP90αProteintechCat#60318-1-Ig; RRID:AB_2881429HSP90βCell Signaling TechnologyCat#5087; RRID:AB_10548761IκBαCell Signaling TechnologyCat#4814; RRID:AB_390781IKKαCell Signaling TechnologyCat#11930; RRID:AB_2687618IKKβCell Signaling TechnologyCat#8943; RRID:AB_11024092Ki67Santa Cruz BiotechnologyCat#sc-7846; RRID:AB_2142374Lamin A/CAbcamCat#ab40567; RRID:AB_775967Lamin B1AbcamCat#ab133741; RRID:AB_2616597LC3Cell Signaling TechnologyCat#3868; RRID:AB_2137707MAP2Sigma-AldrichCat#M4403; RRID:AB_477193NF-κB p65Cell Signaling TechnologyCat#8242; RRID:AB_10859369p62Cell Signaling TechnologyCat#88588; RRID:AB_2800125p70S6KCell Signaling TechnologyCat#2708; RRID:AB_390722Phospho-4EBP1 (Thr37/46)Cell Signaling TechnologyCat#2855; RRID:AB_560835Phospho-AKT (Ser473)Cell Signaling TechnologyCat#9271; RRID:AB_329825Phospho-AKT (Thr308)Cell Signaling TechnologyCat#9275; RRID:AB_329828Phospho-GSK3β (Ser9)Cell Signaling TechnologyCat#9336; RRID:AB_331405Phospho-IκBαCell Signaling TechnologyCat#2859; RRID:AB_561111Phospho-IKKα/βCell Signaling TechnologyCat#2697; RRID:AB_2079382Phospho-NF-κB p65 (Ser536)Cell Signaling TechnologyCat#3303; RRID:AB_331284Phospho-p70S6K (Thr389)Cell Signaling TechnologyCat#9234; RRID:AB_2269803Phospho-SGK1 (Ser78)Cell Signaling TechnologyCat#5599; RRID:AB_10698593pRPS6Cell Signaling TechnologyCat#4858; RRID:AB_916156RIP1Cell Signaling TechnologyCat#3493; RRID:AB_2305314SGK1Cell Signaling TechnologyCat#12103; RRID:AB_2687476THMilliporeCat#AB152; RRID:AB_390204total tau (EP2456Y)AbcamCat#ab76128; RRID:AB_1524475γH2AXCell Signaling TechnologyCat#9718; RRID:AB_2118009γH2AXMilliporeCat#05–636; RRID:AB_309864p-tau (AT8, Ser202/Thr205)Thermo Fisher ScientificCat#MN1020; RRID:AB_223647Alexa Fluor 488 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A11001; RRID:AB_2534069Alexa Fluor 488 goat anti-rabbit IgG (H + L)Thermo Fisher ScientificCat#A11008; RRID:AB_143165Alexa Fluor 555 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A28180; RRID:AB_2536164Alexa Fluor 594 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A11032; RRID:AB_2534091Alexa Fluor 594 goat anti-rabbit IgG (H + L)Thermo Fisher ScientificCat#A11012; RRID:AB_2534079Alexa Fluor 647 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A21236; RRID:AB_2535805Alexa Fluor 647 goat anti-rabbit IgG (H + L)Thermo Fisher ScientificCat#A21245; RRID:AB_2535813Peroxidase-AffiniPure goat anti-mouse IgG (H + L)Jackson ImmunoResearchCat#115-035-146; RRID:AB_2307392Peroxidase-AffiniPure goat anti-rabbit IgG (H + L)Jackson ImmunoResearchCat#111-035-144; RRID:AB_2307391Recombinant DNAAAV1-CAG-tdTomatoAddgeneAddgene #59462Synapsin promoter-driven GFP reporter lentiviral vectorKind gift from Dr. Hiroyuki Miyoshi, Keio UniversityN/AChemicals, peptides, and recombinant proteins17-DMAGSelleck ChemicalsCat#S11422-mercaptoethanolSigma-AldrichCat#M3148ABT-737Selleck ChemicalsCat#S1002AccutaseNacalai TesqueCat#12679-54Ascorbic acidSigma-AldrichCat#A5960AZD0156Selleck ChemicalsCat#S8375AzithromycinSelleck ChemicalsCat#S1835B27 Plus SupplementThermo Fisher ScientificCat#A3582801B27 SupplementThermo Fisher ScientificCat#12587-010Bafilomycin A1Selleck ChemicalsCat#S1413Brain-derived neurotrophic factor (BDNF)BioLegendCat#788904CHIR99021Nacalai TesqueCat#18764-44CultureOneThermo Fisher ScientificCat#A3320201DasatinibSelleck ChemicalsCat#S1021DAPTSigma-AldrichCat#D5942Dibutyryl-cAMPNacalai TesqueCat#11540-61Dissociation solution for human ES/iPS cellsREPROCELLCat#RCHETP002DMEMNacalai TesqueCat#08458-16DMEM/F12Sigma-AldrichCat#D6421DoxycyclineSelleck ChemicalsCat#S4163ECL Prime Western Blotting Detection ReagentCytivaCat#RPN2236Fibroblast growth factor 2 (FGF2)PeproTechCat#100-18BFibronectinCorningCat#356008FisetinSelleck ChemicalsCat#S2298G418RocheCat#G418-ROGlial cell line-derived neurotrophic factor (GDNF)PeproTechCat#450-10Human leukemia inhibitory factor (hLIF)Nacalai TesqueCat#NU0013-1Inhibitor librarySigma-AldrichCat#BMINH02MARUNiMatrix-511NippiCat#892012KnockOut Serum ReplacementThermo Fisher ScientificCat#10828-028KU55933Selleck ChemicalsCat#S1092KU60019Sigma-AldrichCat#SML1416KU60019Selleck ChemicalsCat#S1570KBM neural stem cell mediumKohjin-BioCat#16050100LamininThermo Fisher ScientificCat#23017015LDN-193189Selleck ChemicalsCat#S2618L-glutamineSigma-AldrichCat#G7513MetforminSelleck ChemicalsCat#S5958MIRINCayman ChemicalCat#13208NEBNext Ultra RNA Library Prep Kit for IlluminaNew England BiolabsCat#E7770NuPAGE LDS Sample BufferThermo Fisher ScientificCat#NP0007Penicillin-StreptomycinInvitrogenCat#15140122PhosSTOPRocheCat#04906845001Poly-L-lysineSigma-AldrichCat#P4707Poly-L-ornithineSigma-AldrichCat#P3655Protease inhibitor cocktailRocheCat#04693132001PuromycinNacalai TesqueCat#14861-71QuercetinSigma-AldrichCat#S2391RapamycinSelleck ChemicalsCat#S1039RIPA Lysis and Extraction BufferThermo Fisher ScientificCat#89900RNeasy Plus Mini KitQIAGENCat#74134SB431542Nacalai TesqueCat#18176-54StemFit AK02NTakara BioCat#AK02NSTEM-CELLBANKERTakara BioCat#11924/CB045SYBR Premix Ex Taq IITakara BioCat#RR820Transforming growth factor β3 (TGF-β3)BioLegendCat#585802TrypLE SelectThermo Fisher ScientificCat#12563-029VE821Sigma-AldrichCat#SML1415XAV939Selleck ChemicalsCat#S1180Y-27632FUJIFILM WakoCat#257-00614Critical commercial assays7-Aminoactinomycin D (7-AAD)Nacalai TesqueCat#19175-34Annexin V-FITC Apoptosis Detection KitNacalai TesqueCat#15342-54Caspase-Glo 3/7 Assay SystemPromegaCat#G8090CellTiter-Blue Cell Viability AssayPromegaCat#G8080CellTiter-Glo 2.0 Cell Viability AssayPromegaCat#G9241Human β-amyloid (1–40) ELISA kitFUJIFILM WakoCat#292-62301Human β-amyloid (1–42) ELISA kitFUJIFILM WakoCat#294-62501Human Cytokine Array C1000RayBiotechCat#AAH-CYT-1000-8NAD/NADH-Glo AssayPromegaCat#G9071SPiDER-βGalDojindo Molecular TechnologiesCat#SG03Deposited dataRNA-seq data from this studyThis studyDRA: PRJDB17588Experimental models: Cell linesHuman iPSC line: 201B7: control; F, 36 years; dermal fibroblasts; retrovirus; on-feeder(Takahashi et al., 2007)201B7Human iPSC line: WD39: control; F, 16 years; dermal fibroblasts; retrovirus; feeder-free(Imaizumi et al., 2012)WD39Human iPSC line: C1: control; F, 24 years; PBMC; Sendai virus; on-feeder(Hoashi et al., 2017)C1Human iPSC line: C2: control; M, 30 years; PBMC; Sendai virus; on-feeder(Hoashi et al., 2017)C2Human iPSC line: TKA4: control; M, 40 years; PBMC; Sendai virus; on-feeder(Matsumoto et al., 2016)TKA4Human iPSC line: JA5: control; M, 47 years; PBMC; Sendai virus; feeder-free(Ishikawa et al., 2024b)JUCGRMi005-A (JA5)Human iPSC line: JB6: control; F, 55 years; PBMC; Sendai virus; feeder-free(Ishikawa et al., 2024c)JUCGRMi006-A (JB6)Human iPSC line: JC9: control; M, 70 years; PBMC; Sendai virus; feeder-freeThis paperJC9Human iPSC line: PS1: PSEN1 c.737C>A (p.Ala246Glu); F, 31 years; PBMC; Sendai virus; feeder-freeCoriell InstituteAG25367Human iPSC line: PH7: PARK2 exon 3 homozygous deletion; F, 25 years; PBMC; Sendai virus; feeder-free(Ishikawa et al., 2024a)JUCGRMi003-A (PH7)Human iPSC line: PKB4: PARK6 c.1162T>C (p.Cys388Arg); F, 61 years; dermal fibroblasts; retrovirus; feeder-free(Shiba-Fukushima et al., 2017)PKB4Human iPSC line: CHA11: PARK22 c.182C>T (p.Thr61Ile); M, 45 years; dermal fibroblasts; episomal vector; feeder-free(Ikeda et al., 2019)CHA11Human dermal fibroblasts: young donor; F, 17 years(Imaizumi et al., 2012)WD (young fibroblasts)Human dermal fibroblasts: aged donor; M, 66 yearsThis paperAged fibroblastsHuman neuroblastoma cell line: SH-SY5YATCCCat#CRL-2266Human hiPSC-derived neurons: ReproNeuro AD-mutation; PSEN1 p.P117LREPROCELLCat#RCDN002NHuman hiPSC-derived neurons: ReproNeuro wild-type controlREPROCELLCat#RCDN001NOligonucleotidesPrimer: NAMPT Forward: TGTTCCAGCAGCAGAACACAThis paperN/APrimer: NAMPT Reverse: GCTGACCACAGATACAGGCAThis paperN/APrimer: NMNAT Forward: GCTGGCCAAGGACTACATGAThis paperN/APrimer: NMNAT Reverse: AGTTCTGCCATGATGACCCGThis paperN/APrimer: LMNB1 Forward: CCTTCTTCCCGTGTGACAGTThis paperN/APrimer: LMNB1 Reverse: AGGCGGAATGAGAGATGCTAThis paperN/APrimer: LMNB2 Forward: CATCTCCGTCATCTCCTGCTThis paperN/APrimer: LMNB2 Reverse: TGGAGTCCCTCAGCTACCAGThis paperN/APrimer: ACTB (β-actin) Forward: TGAAGTGTGACGTGGACATCThis paperN/APrimer: ACTB (β-actin) Reverse: GGAGGAGCAATGATCTTGATThis paperN/ASoftware and algorithmsIN Cell Developer Toolbox v1.9GE HealthcareN/ACellPathfinderYokogawaN/AImageJNIHhttps://imagej.nih.gov/pCLAMP 10.7Molecular DevicesN/AFastQCBabraham Bioinformaticshttps://www.bioinformatics.babraham.ac.uk/projects/fastqc/Trim Galore v0.6.6Babraham Bioinformaticshttps://www.bioinformatics.babraham.ac.uk/projects/trim_galore/HISAT2 v2.2.1(Kim et al., 2015)https://daehwankimlab.github.io/hisat2/SAMtools v1.11(Li et al., 2009)https://www.htslib.org/featureCounts v1.6.4(Liao et al., 2014)https://subread.sourceforge.net/featureCounts.htmledgeRBioconductorhttps://www.bioconductor.org/packages/edgeRclusterProfiler(Wu et al., 2021)https://bioconductor.org/packages/release/bioc/html/clusterProfiler.htmlTCC(Sun et al., 2013)N/AbaySeq(Osabe et al., 2019)N/AplotlyPlotlyhttps://plotly.com/FlowJo v10.8.1BD BiosciencesN/AguavaSoft 3.3MilliporeN/AR v4.4.2R Foundation for Statistical Computinghttps://www.r-project.org/ REAGENT or RESOURCESOURCEIDENTIFIERAntibodies4EBP1Cell Signaling TechnologyCat#9644; RRID:AB_209784153BP1Cell Signaling TechnologyCat#4937; RRID:AB_10694558AKT (total)Cell Signaling TechnologyCat#9272; RRID:AB_329827BAXCell Signaling TechnologyCat#2772; RRID:AB_10695870BCL-2Santa Cruz BiotechnologyCat#sc-7382; RRID:AB_626736β-actinAbcamCat#ab8227; RRID:AB_2305186β3-tubulinSigma-AldrichCat#T8660; RRID:AB_477590Cleaved caspase-3Cell Signaling TechnologyCat#9661; RRID:AB_2341188FOXA2R&D SystemsCat#AF2400; RRID:AB_2294104GSK3βCell Signaling TechnologyCat#12456; RRID:AB_2636978H3K27me3Active MotifCat#39536; RRID:AB_2793247H3K9acActive MotifCat#39585; RRID:AB_2793268Histone H3Cell Signaling TechnologyCat#4499; RRID:AB_10544537HSP90αProteintechCat#60318-1-Ig; RRID:AB_2881429HSP90βCell Signaling TechnologyCat#5087; RRID:AB_10548761IκBαCell Signaling TechnologyCat#4814; RRID:AB_390781IKKαCell Signaling TechnologyCat#11930; RRID:AB_2687618IKKβCell Signaling TechnologyCat#8943; RRID:AB_11024092Ki67Santa Cruz BiotechnologyCat#sc-7846; RRID:AB_2142374Lamin A/CAbcamCat#ab40567; RRID:AB_775967Lamin B1AbcamCat#ab133741; RRID:AB_2616597LC3Cell Signaling TechnologyCat#3868; RRID:AB_2137707MAP2Sigma-AldrichCat#M4403; RRID:AB_477193NF-κB p65Cell Signaling TechnologyCat#8242; RRID:AB_10859369p62Cell Signaling TechnologyCat#88588; RRID:AB_2800125p70S6KCell Signaling TechnologyCat#2708; RRID:AB_390722Phospho-4EBP1 (Thr37/46)Cell Signaling TechnologyCat#2855; RRID:AB_560835Phospho-AKT (Ser473)Cell Signaling TechnologyCat#9271; RRID:AB_329825Phospho-AKT (Thr308)Cell Signaling TechnologyCat#9275; RRID:AB_329828Phospho-GSK3β (Ser9)Cell Signaling TechnologyCat#9336; RRID:AB_331405Phospho-IκBαCell Signaling TechnologyCat#2859; RRID:AB_561111Phospho-IKKα/βCell Signaling TechnologyCat#2697; RRID:AB_2079382Phospho-NF-κB p65 (Ser536)Cell Signaling TechnologyCat#3303; RRID:AB_331284Phospho-p70S6K (Thr389)Cell Signaling TechnologyCat#9234; RRID:AB_2269803Phospho-SGK1 (Ser78)Cell Signaling TechnologyCat#5599; RRID:AB_10698593pRPS6Cell Signaling TechnologyCat#4858; RRID:AB_916156RIP1Cell Signaling TechnologyCat#3493; RRID:AB_2305314SGK1Cell Signaling TechnologyCat#12103; RRID:AB_2687476THMilliporeCat#AB152; RRID:AB_390204total tau (EP2456Y)AbcamCat#ab76128; RRID:AB_1524475γH2AXCell Signaling TechnologyCat#9718; RRID:AB_2118009γH2AXMilliporeCat#05–636; RRID:AB_309864p-tau (AT8, Ser202/Thr205)Thermo Fisher ScientificCat#MN1020; RRID:AB_223647Alexa Fluor 488 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A11001; RRID:AB_2534069Alexa Fluor 488 goat anti-rabbit IgG (H + L)Thermo Fisher ScientificCat#A11008; RRID:AB_143165Alexa Fluor 555 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A28180; RRID:AB_2536164Alexa Fluor 594 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A11032; RRID:AB_2534091Alexa Fluor 594 goat anti-rabbit IgG (H + L)Thermo Fisher ScientificCat#A11012; RRID:AB_2534079Alexa Fluor 647 goat anti-mouse IgG (H + L)Thermo Fisher ScientificCat#A21236; RRID:AB_2535805Alexa Fluor 647 goat anti-rabbit IgG (H + L)Thermo Fisher ScientificCat#A21245; RRID:AB_2535813Peroxidase-AffiniPure goat anti-mouse IgG (H + L)Jackson ImmunoResearchCat#115-035-146; RRID:AB_2307392Peroxidase-AffiniPure goat anti-rabbit IgG (H + L)Jackson ImmunoResearchCat#111-035-144; RRID:AB_2307391Recombinant DNAAAV1-CAG-tdTomatoAddgeneAddgene #59462Synapsin promoter-driven GFP reporter lentiviral vectorKind gift from Dr. Hiroyuki Miyoshi, Keio UniversityN/AChemicals, peptides, and recombinant proteins17-DMAGSelleck ChemicalsCat#S11422-mercaptoethanolSigma-AldrichCat#M3148ABT-737Selleck ChemicalsCat#S1002AccutaseNacalai TesqueCat#12679-54Ascorbic acidSigma-AldrichCat#A5960AZD0156Selleck ChemicalsCat#S8375AzithromycinSelleck ChemicalsCat#S1835B27 Plus SupplementThermo Fisher ScientificCat#A3582801B27 SupplementThermo Fisher ScientificCat#12587-010Bafilomycin A1Selleck ChemicalsCat#S1413Brain-derived neurotrophic factor (BDNF)BioLegendCat#788904CHIR99021Nacalai TesqueCat#18764-44CultureOneThermo Fisher ScientificCat#A3320201DasatinibSelleck ChemicalsCat#S1021DAPTSigma-AldrichCat#D5942Dibutyryl-cAMPNacalai TesqueCat#11540-61Dissociation solution for human ES/iPS cellsREPROCELLCat#RCHETP002DMEMNacalai TesqueCat#08458-16DMEM/F12Sigma-AldrichCat#D6421DoxycyclineSelleck ChemicalsCat#S4163ECL Prime Western Blotting Detection ReagentCytivaCat#RPN2236Fibroblast growth factor 2 (FGF2)PeproTechCat#100-18BFibronectinCorningCat#356008FisetinSelleck ChemicalsCat#S2298G418RocheCat#G418-ROGlial cell line-derived neurotrophic factor (GDNF)PeproTechCat#450-10Human leukemia inhibitory factor (hLIF)Nacalai TesqueCat#NU0013-1Inhibitor librarySigma-AldrichCat#BMINH02MARUNiMatrix-511NippiCat#892012KnockOut Serum ReplacementThermo Fisher ScientificCat#10828-028KU55933Selleck ChemicalsCat#S1092KU60019Sigma-AldrichCat#SML1416KU60019Selleck ChemicalsCat#S1570KBM neural stem cell mediumKohjin-BioCat#16050100LamininThermo Fisher ScientificCat#23017015LDN-193189Selleck ChemicalsCat#S2618L-glutamineSigma-AldrichCat#G7513MetforminSelleck ChemicalsCat#S5958MIRINCayman ChemicalCat#13208NEBNext Ultra RNA Library Prep Kit for IlluminaNew England BiolabsCat#E7770NuPAGE LDS Sample BufferThermo Fisher ScientificCat#NP0007Penicillin-StreptomycinInvitrogenCat#15140122PhosSTOPRocheCat#04906845001Poly-L-lysineSigma-AldrichCat#P4707Poly-L-ornithineSigma-AldrichCat#P3655Protease inhibitor cocktailRocheCat#04693132001PuromycinNacalai TesqueCat#14861-71QuercetinSigma-AldrichCat#S2391RapamycinSelleck ChemicalsCat#S1039RIPA Lysis and Extraction BufferThermo Fisher ScientificCat#89900RNeasy Plus Mini KitQIAGENCat#74134SB431542Nacalai TesqueCat#18176-54StemFit AK02NTakara BioCat#AK02NSTEM-CELLBANKERTakara BioCat#11924/CB045SYBR Premix Ex Taq IITakara BioCat#RR820Transforming growth factor β3 (TGF-β3)BioLegendCat#585802TrypLE SelectThermo Fisher ScientificCat#12563-029VE821Sigma-AldrichCat#SML1415XAV939Selleck ChemicalsCat#S1180Y-27632FUJIFILM WakoCat#257-00614Critical commercial assays7-Aminoactinomycin D (7-AAD)Nacalai TesqueCat#19175-34Annexin V-FITC Apoptosis Detection KitNacalai TesqueCat#15342-54Caspase-Glo 3/7 Assay SystemPromegaCat#G8090CellTiter-Blue Cell Viability AssayPromegaCat#G8080CellTiter-Glo 2.0 Cell Viability AssayPromegaCat#G9241Human β-amyloid (1–40) ELISA kitFUJIFILM WakoCat#292-62301Human β-amyloid (1–42) ELISA kitFUJIFILM WakoCat#294-62501Human Cytokine Array C1000RayBiotechCat#AAH-CYT-1000-8NAD/NADH-Glo AssayPromegaCat#G9071SPiDER-βGalDojindo Molecular TechnologiesCat#SG03Deposited dataRNA-seq data from this studyThis studyDRA: PRJDB17588Experimental models: Cell linesHuman iPSC line: 201B7: control; F, 36 years; dermal fibroblasts; retrovirus; on-feeder(Takahashi et al., 2007)201B7Human iPSC line: WD39: control; F, 16 years; dermal fibroblasts; retrovirus; feeder-free(Imaizumi et al., 2012)WD39Human iPSC line: C1: control; F, 24 years; PBMC; Sendai virus; on-feeder(Hoashi et al., 2017)C1Human iPSC line: C2: control; M, 30 years; PBMC; Sendai virus; on-feeder(Hoashi et al., 2017)C2Human iPSC line: TKA4: control; M, 40 years; PBMC; Sendai virus; on-feeder(Matsumoto et al., 2016)TKA4Human iPSC line: JA5: control; M, 47 years; PBMC; Sendai virus; feeder-free(Ishikawa et al., 2024b)JUCGRMi005-A (JA5)Human iPSC line: JB6: control; F, 55 years; PBMC; Sendai virus; feeder-free(Ishikawa et al., 2024c)JUCGRMi006-A (JB6)Human iPSC line: JC9: control; M, 70 years; PBMC; Sendai virus; feeder-freeThis paperJC9Human iPSC line: PS1: PSEN1 c.737C>A (p.Ala246Glu); F, 31 years; PBMC; Sendai virus; feeder-freeCoriell InstituteAG25367Human iPSC line: PH7: PARK2 exon 3 homozygous deletion; F, 25 years; PBMC; Sendai virus; feeder-free(Ishikawa et al., 2024a)JUCGRMi003-A (PH7)Human iPSC line: PKB4: PARK6 c.1162T>C (p.Cys388Arg); F, 61 years; dermal fibroblasts; retrovirus; feeder-free(Shiba-Fukushima et al., 2017)PKB4Human iPSC line: CHA11: PARK22 c.182C>T (p.Thr61Ile); M, 45 years; dermal fibroblasts; episomal vector; feeder-free(Ikeda et al., 2019)CHA11Human dermal fibroblasts: young donor; F, 17 years(Imaizumi et al., 2012)WD (young fibroblasts)Human dermal fibroblasts: aged donor; M, 66 yearsThis paperAged fibroblastsHuman neuroblastoma cell line: SH-SY5YATCCCat#CRL-2266Human hiPSC-derived neurons: ReproNeuro AD-mutation; PSEN1 p.P117LREPROCELLCat#RCDN002NHuman hiPSC-derived neurons: ReproNeuro wild-type controlREPROCELLCat#RCDN001NOligonucleotidesPrimer: NAMPT Forward: TGTTCCAGCAGCAGAACACAThis paperN/APrimer: NAMPT Reverse: GCTGACCACAGATACAGGCAThis paperN/APrimer: NMNAT Forward: GCTGGCCAAGGACTACATGAThis paperN/APrimer: NMNAT Reverse: AGTTCTGCCATGATGACCCGThis paperN/APrimer: LMNB1 Forward: CCTTCTTCCCGTGTGACAGTThis paperN/APrimer: LMNB1 Reverse: AGGCGGAATGAGAGATGCTAThis paperN/APrimer: LMNB2 Forward: CATCTCCGTCATCTCCTGCTThis paperN/APrimer: LMNB2 Reverse: TGGAGTCCCTCAGCTACCAGThis paperN/APrimer: ACTB (β-actin) Forward: TGAAGTGTGACGTGGACATCThis paperN/APrimer: ACTB (β-actin) Reverse: GGAGGAGCAATGATCTTGATThis paperN/ASoftware and algorithmsIN Cell Developer Toolbox v1.9GE HealthcareN/ACellPathfinderYokogawaN/AImageJNIHhttps://imagej.nih.gov/pCLAMP 10.7Molecular DevicesN/AFastQCBabraham Bioinformaticshttps://www.bioinformatics.babraham.ac.uk/projects/fastqc/Trim Galore v0.6.6Babraham Bioinformaticshttps://www.bioinformatics.babraham.ac.uk/projects/trim_galore/HISAT2 v2.2.1(Kim et al., 2015)https://daehwankimlab.github.io/hisat2/SAMtools v1.11(Li et al., 2009)https://www.htslib.org/featureCounts v1.6.4(Liao et al., 2014)https://subread.sourceforge.net/featureCounts.htmledgeRBioconductorhttps://www.bioconductor.org/packages/edgeRclusterProfiler(Wu et al., 2021)https://bioconductor.org/packages/release/bioc/html/clusterProfiler.htmlTCC(Sun et al., 2013)N/AbaySeq(Osabe et al., 2019)N/AplotlyPlotlyhttps://plotly.com/FlowJo v10.8.1BD BiosciencesN/AguavaSoft 3.3MilliporeN/AR v4.4.2R Foundation for Statistical Computinghttps://www.r-project.org/ Experimental model and study participant details Culture of hiPSCs The hiPSC lines used in this study are listed in the key resources table. Their basic characterization, including authentication, pluripotency, genomic characterization, and genetic mutations, has been described in previous reports, and the cells were cryopreserved using STEM-CELLBANKER. All hiPSCs were used at passages 20–50 and were routinely tested for mycoplasma contamination and sterility. For on-feeder culture, hiPSCs were maintained on mitomycin C-treated SNL murine fibroblast feeder cells in DMEM/F12 supplemented with 20% KnockOut Serum Replacement, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 0.1 mM 2-mercaptoethanol, 0.5% penicillin/streptomycin, and 4 ng/mL fibroblast growth factor 2 (FGF2) under a 3% CO2 atmosphere. Cells were passaged every 7 days using a dissociation solution at a 1:5 split ratio. For feeder-free culture, hiPSCs were maintained on iMatrix-511-coated plates in StemFit AK02N medium under a 5% CO2 atmosphere and passaged every 7 days using TrypLE Select at a split density of 1.5 × 103 cells/cm2. All experimental procedures involving hiPSCs were approved by the Juntendo University School of Medicine Ethics Committee (M08-0449) and the Keio University School of Medicine Ethics Committee (20080016). Culture of human dermal fibroblasts The human dermal fibroblasts used in this study are listed in the key resources table. Cells were maintained in high-glucose DMEM supplemented with 10% fetal bovine serum (FBS) and 100 U/mL penicillin-streptomycin at 37°C under a 5% CO2 atmosphere. Cells at passages 4–7 were used for all experiments. Unless otherwise specified, cells were treated with 10 μM KU60019. All experimental procedures involving fibroblasts were approved by the Keio University School of Medicine Ethics Committee (20-16-18). Culture of SH-SY5Y cells SH-SY5Y cells were maintained in high-glucose DMEM supplemented with 10% FBS and 100 U/mL penicillin-streptomycin at 37°C under a 5% CO2 atmosphere. Unless otherwise specified, cells were treated with 10 μM KU60019 for 72 h prior to analysis. Human hiPSC-derived neurons for PSEN1 assays For cell viability and Aβ ELISA assays, hiPSC-derived neurons carrying the PSEN1 p.P117L mutation (ReproNeuro AD-mutation, RCDN002N) and wild-type control neurons (ReproNeuro, RCDN001N) were used according to the manufacturer’s instructions. Cells were cultured in ReproNeuro culture medium for 14–30 days in the presence or absence of 5 μM KU60019 prior to analysis. Sex information for the commercially obtained ReproNeuro cells was not available from the provider. Method details Differentiation of hiPSCs into dopaminergic neurons Dopaminergic neuron progenitor cells were generated from hiPSCs using two previously established methods: neurosphere-based differentiation (Nakamura et al., 2023) and floor plate-based differentiation from feeder-free hiPSCs (Gantner et al., 2020). Progenitor cells obtained by both methods were plated onto poly-L-ornithine- and fibronectin-coated plates for terminal differentiation. Cells were cultured in KBM neural stem cell medium supplemented with B27 Plus, CultureOne, 20 ng/mL brain-derived neurotrophic factor (BDNF), 20 ng/mL glial cell line-derived neurotrophic factor (GDNF), 0.2 mM ascorbic acid, 0.5 mM dibutyryl cyclic AMP (dbcAMP), 1 ng/mL transforming growth factor β3 (TGF-β3), 10 μM DAPT, 3 μM CHIR99021, and 10 μM Y-27632. Half of the medium was replaced every 3–4 days with fresh medium lacking CHIR99021 and Y-27632. KU60019 (5 μM) was added at the time of seeding of neural progenitor cells and maintained throughout the differentiation period, typically 14 days, until analysis. Compound screening For compound screening, 201B7 hiPSCs were dissociated and seeded at a density of 10 cells/μL in KBM neural stem cell medium supplemented with B27, 20 ng/mL FGF2, 10 ng/mL hLIF, and 10 μM Y-27632 under a 3% CO2 atmosphere to form floating neurospheres. Neurospheres were dissociated using TrypLE Select and passaged up to six times. Dissociated neurospheres were then plated onto poly-L-ornithine- and fibronectin-coated plates and cultured in KBM neural stem cell medium supplemented with B27, 20 ng/mL BDNF, 20 ng/mL GDNF, 200 μM ascorbic acid, 0.5 mM dbcAMP, and 1 ng/mL TGF-β3. Cells were infected with a lentiviral vector encoding a synapsin promoter-driven GFP reporter. After 24 h, the medium was replaced with an inhibitor library at a final concentration of 10 μM. The medium was subsequently replaced every 2–3 days. After 17 days of differentiation, neuronal maturation was quantified based on the mean GFP fluorescence intensity in each well using an IN Cell Analyzer 1000. Senolytic drug treatment Young fibroblasts were cultured with 10 μM KU60019 for 2 days. The medium was then replaced with fresh medium containing 10 μM KU60019 and 10 μM senolytic drugs, followed by incubation for 24 h. The following senolytic drugs were used: rapamycin, metformin, ABT-737, 17DMAG, azithromycin, fisetin, dasatinib, and quercetin. For hiPSC-derived neurons, 2.5 μM 17DMAG was added during the final 3 days of a 14-day differentiation period in the presence of 5 μM KU60019. Immunostaining and quantification Cells were fixed in 4% paraformaldehyde for 30 min and blocked with 5% fetal bovine serum and 0.1% Triton X-100 for 30 min at room temperature (23°C–27°C). Cells were then incubated with primary antibodies diluted in blocking solution at 4°C for 12–18 h. After washing with phosphate-buffered saline, cells were incubated with appropriate secondary antibodies and Hoechst 33258 (0.5 μg/mL) for 1 h at room temperature. Images were acquired using BZ-X800, IN Cell Analyzer 2200, or a CQ1 confocal image cytometer. For quantification, images were randomly acquired from 16 fields per well using the IN Cell Analyzer 2200 and analyzed with IN Cell Developer Toolbox v1.9. When co-stained with MAP2, analyses were restricted to MAP2-positive cells. For assessment of Lamin B1-associated nuclear abnormalities, cells with abnormal nuclear morphology were defined as those exhibiting a luminance value <1500 and a perinuclear length of 0.5–0.8, as previously described (Freund et al., 2012). For DNA damage analysis, cells containing three or more nuclear γH2AX or 53BP1 foci were classified as positive (Zorin et al., 2019). For analysis of CCF and SA-βGal-positive cell populations, as well as p-tau and total tau detection, images were acquired using a CQ1 confocal image cytometer and analyzed with CellPathfinder. The pTau/Tau ratio was calculated as the ratio of integrated fluorescence intensities (area × mean intensity) and averaged per well. SA-βGal staining and quantification SA-βGal staining was performed using the Cellular Senescence Detection Kit - SPiDER-βGal according to the manufacturer’s instructions. Prior to staining, the medium was replaced with medium supplemented with 1 μM bafilomycin A1, and cells were incubated at 37°C for 1 h. Cells were then stained with 20 μM SPiDER-βGal solution at 37°C for 1 h and fixed in 4% paraformaldehyde for 30 min. Following SA-βGal staining, immunostaining was performed as described above. Neurons were identified by MAP2 staining where applicable. Images were acquired using BZ-X800, IN Cell Analyzer 2200, or a CQ1 confocal image cytometer, and quantified using the same criteria as described above. For flow cytometric analysis, SA-βGal-positive cells were quantified using a Guava easyCyte System. Sparse labeling and neurite length measurement hiPSC-derived secondary neurospheres containing dopaminergic neuron progenitors were dissociated using Accutase and cryopreserved in STEM-CELLBANKER. Cells were thawed, infected with AAV1-CAG-tdTomato for 15 min, plated on poly-L-lysine-coated 35-mm plastic dishes at a density of 2 × 10ˆ4 cells/dish, and co-cultured with unlabeled cells at a density of 48 × 10ˆ4 cells/dish. The culture medium was replaced with KBM neural stem cell medium supplemented with 2% B27, 20 ng/mL BDNF, 20 ng/mL GDNF, 0.2 mM ascorbic acid, 0.5 mM dbcAMP, 1 ng/mL TGF-β3, and 10 μM DAPT, with or without 5 μM KU60019. tdTomato-labeled cells were imaged at 3, 5, and 7 days after plating using an iX73 microscope with ×4 and ×10 dry objectives. The length of the longest neurite per cell was measured using ImageJ. Whole-cell patch-clamp recordings Coverslips containing hiPSC-derived neurons treated with or without KU60019 were transferred to a recording chamber mounted on the stage of an Olympus BX51WI upright microscope equipped with an infrared differential interference contrast imaging system. For KU60019-treated samples, treatment was maintained until the time of recording. Recordings were performed in a standard extracellular solution maintained at 23°C–27°C, containing 130 mM NaCl, 26 mM NaHCO3, 10 mM glucose, 3 mM KCl, 2 mM CaCl2, 2 mM MgCl2, and 1.25 mM NaH2PO4. The solution was continuously perfused at 1–2 mL/min and oxygenated with 95% O2 and 5% CO2 to maintain pH 7.4. Neurons with a compact soma and at least two extended processes were selected for recording. Patch pipettes were fabricated from borosilicate glass capillaries (GD-1.5; Narishige) using a P-97 puller (Sutter Instrument). The internal solution (pH 7.25, 285–300 mOsm) contained 10 mM KCl, 130 mM K-gluconate, 10 mM HEPES, 0.4 mM EGTA, 2 mM MgCl2, 0.3 mM Na2-GTP, and 2 mM Mg-ATP. Pipette resistance ranged from 2.5 to 5.0 MΩ. Electrophysiological signals were recorded using a MultiClamp 700B amplifier, filtered at 10 kHz, and digitized at 20 kHz using a Digidata 1440A. Access resistance was continuously monitored throughout the recordings. Data were analyzed using pCLAMP 10.7. Voltage responses were recorded in current-clamp mode by applying 300 ms current steps from −60 pA to +150 pA in 10 pA increments at a holding potential of −60 mV, delivered at 0.5 Hz. Western blotting Cells were lysed in RIPA buffer supplemented with a protease inhibitor cocktail and PhosSTOP, followed by centrifugation at 15,300 × g for 15 min at 4°C. The supernatant was mixed with NuPAGE LDS sample buffer, and proteins were separated by SDS-PAGE. Proteins were transferred onto PVDF membranes, which were then blocked with PVDF Blocking Reagent for Can Get Signal and incubated with primary antibodies at 4°C for 12–18 h. After washing, membranes were incubated with appropriate secondary antibodies for 1 h, and immunoreactive signals were detected by chemiluminescence using ECL Prime reagent and a Fusion Solo 7S imaging system. Measurement of total NAD/NADH Intracellular NAD/NADH levels were measured using a NAD/NADH-Glo Assay. Neurons were cultured in 96-well plates for 14 days, and an equal volume of the reaction solution was added to each well according to the manufacturer’s instructions with gentle agitation. Luminescence was measured using a Mithras LB943 multimode plate reader. Cytokine array Young fibroblasts were cultured in serum-free medium with or without KU60019 for 3 days. Cytokines in the conditioned medium were detected using a Human Cytokine Array C1000 according to the manufacturer’s instructions. Membranes were first incubated with blocking buffer for 30 min at room temperature, followed by incubation with samples at 4°C for 12–18 h. After washing with the provided wash buffer, membranes were incubated with a biotinylated antibody cocktail at 4°C for 12–18 h. Membranes were then washed and incubated with HRP-conjugated streptavidin for 2 h at room temperature. After additional washing, signals were developed using the detection buffer. Images were acquired using a Fusion Solo 7S imaging system and quantified using ImageJ. Signal intensities were normalized to total cellular protein content. Quantitative reverse transcription PCR and RNA-seq analysis Total RNA was extracted from cells using the RNeasy Plus Mini Kit and reverse-transcribed to generate cDNA. Quantitative RT-PCR was performed using a QuantStudio 6 Real-Time PCR System with SYBR Premix Ex Taq II and gene-specific primers. Primer sequences are provided in the key resources table. For RNA-seq analysis, libraries were prepared using the NEBNext Ultra RNA Library Prep Kit for Illumina with poly(A) selection according to the manufacturer’s instructions. Libraries were sequenced on a NovaSeq 6000 with a read depth of >20 million reads per sample. The RNA-seq data have been deposited in the DDBJ Sequence Read Archive (accession number: PRJDB17588). Raw sequence data were quality-checked using FastQC and processed with TrimGalore v0.6.6. Reads were mapped to the human reference genome (GRCh38) using HISAT2 v2.2.1 (Kim et al., 2015). BAM files were generated using SAMtools v1.11 (Li et al., 2009), and gene-level read counts were obtained using featureCounts v1.6.4 (Liao et al., 2014). Differential expression analysis was performed using the edgeR package based on a generalized linear model framework (Sun et al., 2013). Genes with |log2 fold change| ≥ 1 and a false discovery rate <0.05 were defined as differentially expressed genes. Functional enrichment analysis was performed using the enrichKEGG function in the clusterProfiler package (Wu et al., 2021). For multi-group comparisons, normalized count data obtained using TCC normalization were analyzed using the baySeq algorithm with an empirical Bayesian approach (Osabe et al., 2019). Principal component analysis was performed on log10(x + 1)-transformed data and visualized in 3D using the plotly package. PSEN1-variant hiPSC-derived neurons For p-tau/total tau analysis, hiPSCs were differentiated into cortical excitatory neurons based on a previously reported protocol combining NGN2 programming with developmental patterning (Kondo et al., 2017), with minor modifications. To induce neuronal differentiation, hiPSCs carrying a piggyBac-integrated, doxycycline-inducible NGN2 cassette were seeded onto iMatrix-511-coated plates in StemFit AK02N medium supplemented with Y-27632. On day 1, the medium was replaced with KBM neural stem cell medium supplemented with B27 Plus, doxycycline, SB431542 (10 μM), LDN-193189 (100 nM), and XAV939 (2 μM) for 2 days. On day 3, inhibitors were removed and puromycin/G418 selection was applied. On day 4, cells were dissociated using Accutase and replated onto poly-L-ornithine/laminin-coated plates, defined as DIV0. Neurons were maintained in maturation medium consisting of KBM neural stem cell medium supplemented with B27 Plus, 200 μM ascorbic acid, 500 μM dbcAMP, 20 ng/mL BDNF, and 20 ng/mL GDNF, with half-volume medium changes twice per week. KU60019 (5 μM) was added to the maturation medium from DIV0 to DIV14. Cells were subsequently maintained without KU60019 and analyzed at DIV28 or DIV42. Measurement of Aβ40 and Aβ42 by ELISA For Aβ ELISA assays, neurons were seeded in 96-well plates at a density of 1 × 10ˆ5 cells/well. The following day, the medium was replaced with ReproNeuro culture medium supplemented with 5 μM KU60019. Culture supernatants were collected on days 21 and 30 to measure Aβ40 and Aβ42 levels using human β-amyloid (1–40) and human β-amyloid (1–42) ELISA kits, respectively. The Aβ42/40 ratio was calculated using culture supernatants collected from the same well. Cell viability and caspase-3/7 assays The viability of neurons or fibroblasts cultured in 96-well plates was measured using the CellTiter-Glo 2.0 Cell Viability Assay according to the manufacturer’s instructions. Luminescence was measured using a Mithras LB943 multimode plate reader. For caspase-3/7 activity measurements, the viability of hiPSC-derived neurons was first assessed in the same wells using CellTiter-Blue reagent, and fluorescence intensity was used as an internal control. Caspase-3/7 activity was then measured using the Caspase-Glo 3/7 Assay System following incubation for 1 h. Luminescence was measured using the same plate reader, and caspase-3/7 activity was normalized to the corresponding CellTiter-Blue fluorescence intensity. Annexin V/7-AAD apoptosis assay Neurons were dissociated using Accutase and stained with an Annexin V-FITC Apoptosis Detection Kit and 7-aminoactinomycin D according to the manufacturer’s instructions. Data were acquired using a Guava easyCyte System and analyzed using FlowJo v10.8.1, R v4.4.2, and guavaSoft 3.3. Apoptotic cells were identified based on Annexin V and 7-AAD staining. Quantification and statistical analysis Statistical analysis Data are presented as mean ± standard error of the mean (SEM). Statistical significance was defined as p ≤ 0.05. Statistical analyses were performed using R v4.4.2. Exact statistical tests, sample sizes, and the definition of n for each experiment are provided in the figure legends.